MLM Medical Labs (“MLM”) is pleased to announce that Scott Houlton has joined the company as the new Chief Executive Officer and Roger Gasper as the Chief Financial Officer. Mr. Houlton brings over 25 years of life sciences experience to MLM. Most recently Mr. Houlton served as CEO of Clinical Supplies Management, Inc. (“CSM”), which specialized in managing global clinical trials for biotech and pharmaceutical companies. CSM was a previous portfolio company of Great Point Partners (“GPP”) who is the lead investor in MLM. CSM successfully integrated three international clinical supply companies and achieved significant growth before being acquired by Clinigen Group, based in the United Kingdom. Prior to CSM, Mr. Houlton was President at Catalent, Chief Operating Officer at Aptuit, Inc. and held leadership positions at Quintiles and Cardinal Health.
“I am excited to join the talented team at MLM and look forward to helping grow the business now that MLM has acquired two specialty labs in the US with CirQuest Labs and MD Biosciences. The specialty and safety lab testing that MLM now offers in both the US and Europe provides our customers the scientific expertise they need with the flexible, high-touch customer service that is often missing from the large laboratories,” stated Mr. Houlton.
MLM also announced that Roger Gasper has been named Chief Financial Officer. Mr. Gasper has an established track record in both private and public companies. Most recently Mr. Gasper served as CFO at MaSTherCell Global, a leading cell and gene therapy contract development and manufacturing partner recently acquired by Catalent. Prior to MaSTherCell (also a GPP portfolio company), Mr. Gasper worked with Mr. Houlton as CFO at CSM and was previously CFO at The J.G. Wentworth Company.
“We are fortunate to be able to work with both Scott and Roger again with MLM after having achieved great results together in our previous investments in both CSM and MaSTherCell”, said Mr. Rohan Saikia, Managing Director at Great Point Partners. “GPP has already supported MLM with two tuck-in acquisitions in the US and we look forwardtothecontinuedgrowthofMLM. WewouldliketothankDr.StephanWnendt for his success in building MLM and his partnership with GPP.”
“I am excited to join the talented team at MLM and look forward to helping grow the business now that MLM has acquired two specialty labs in the US with CirQuest Labs and MD Biosciences. The specialty and safety lab testing that MLM now offers in both the US and Europe provides our customers the scientific expertise they need with the flexible, high-touch customer service that is often missing from the large laboratories,” stated Mr. Houlton.
MLM also announced that Roger Gasper has been named Chief Financial Officer. Mr. Gasper has an established track record in both private and public companies. Most recently Mr. Gasper served as CFO at MaSTherCell Global, a leading cell and gene therapy contract development and manufacturing partner recently acquired by Catalent. Prior to MaSTherCell (also a GPP portfolio company), Mr. Gasper worked with Mr. Houlton as CFO at CSM and was previously CFO at The J.G. Wentworth Company.
“We are fortunate to be able to work with both Scott and Roger again with MLM after having achieved great results together in our previous investments in both CSM and MaSTherCell”, said Mr. Rohan Saikia, Managing Director at Great Point Partners. “GPP has already supported MLM with two tuck-in acquisitions in the US and we look forwardtothecontinuedgrowthofMLM. WewouldliketothankDr.StephanWnendt for his success in building MLM and his partnership with GPP.”
About MLM Medical Labs
MLM Medical Labs is a global central and specialty laboratory with locations in Germany and the US. An international team of over 150 highly skilled and experienced employees support between 190 and 210 clinical trials, phase I–IV, at any given time. MLM offers a broad range of services including, safety testing, analysis of biomarkers, drugs and metabolites, histology, preclinical services, assay development, and kit building. The company is headquartered in Moenchengladbach, Germany (near Düsseldorf) and has branches in Memphis, TN, and Minneapolis, MN, USA. For more information, please visit https://www.mlm-labs.com.
About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.3 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $750 million). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, medical device, information technology enabled businesses and alternate site care. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.
MLM Medical Labs is a global central and specialty laboratory with locations in Germany and the US. An international team of over 150 highly skilled and experienced employees support between 190 and 210 clinical trials, phase I–IV, at any given time. MLM offers a broad range of services including, safety testing, analysis of biomarkers, drugs and metabolites, histology, preclinical services, assay development, and kit building. The company is headquartered in Moenchengladbach, Germany (near Düsseldorf) and has branches in Memphis, TN, and Minneapolis, MN, USA. For more information, please visit https://www.mlm-labs.com.
About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.3 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $750 million). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, medical device, information technology enabled businesses and alternate site care. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.